Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 52 clinical trials
  • 7 views
  • 15 Oct, 2022
  • 8 locations
Ulipristal Acetate for Use in Early Pregnancy Loss

The investigators will study the feasibility of using 90mg ulipristal acetate, a selective progesterone receptor agonist, as an adjunct to 800mcg vaginal misoprostol for the medical management

  • 0 views
  • 28 Jun, 2022
  • 4 locations
Utilization of Patient Reported Outcomes Generated by Electronic Medical Record and Smart Pill Bottles With Follow up Telehealth Encounters to Improve Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients

This phase II trial studies how well telehealth works in improving adherence to endocrine (anti-estrogen) therapy in participants with estrogen receptor and/or progesterone receptor positive

breast surgery
hormone therapy
progesterone
breast cancer staging
estrogen receptor
  • 11 views
  • 25 Oct, 2022
  • 4 locations
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer

The purpose of the study is to evaluate the impact on progression-free survival (PFS) with the combination carboplatin - pembrolizumab in patients with CTC (circulating tumor cells) positive, HER2 negative metastatic breast cancer previously treated with anthracyclines and taxanes. Previous studies have indicated that recurrent breast cancers are more resistant …

biomarker analysis
measurable disease
aptt
neutrophil count
breast cancer
  • 25 views
  • 29 Jan, 2022
  • 1 location
Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

This phase II trial studies how well pembrolizumab works in treating patients with stage IV inflammatory breast cancer or triple-negative breast cancer that has spread to other places in the body (metastatic) or has come back (recurrent), and who have achieved clinical response or stable disease to prior chemotherapy. Immunotherapy …

biomarker analysis
measurable disease
neutrophil count
pleural effusion
absolute neutrophil count
  • 32 views
  • 07 Oct, 2022
  • 1 location
Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer

This phase I trial studies the side effects and best dose of ruxolitinib phosphate when given together with pembrolizumab in treating patients with stage IV triple negative breast cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune …

biomarker analysis
measurable disease
neutrophil count
monoclonal antibody therapy
immunohistochemistry
  • 42 views
  • 27 Apr, 2022
  • 1 location
Leflunomide in Previously Treated Metastatic Triple Negative Cancers

Triple negative breast cancer (TNBC) represents about 15% of breast cancers and is characterized by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and HER-2 non

erbb2
progesterone
breast cancer
estrogen receptor
stage iv breast cancer
  • 10 views
  • 16 Jun, 2022
  • 3 locations
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC

newly diagnosed estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+) metastatic breast cancer may be eligible.

measurable disease
aromatase inhibitor
erbb2
hormone therapy
HER2
  • 14 views
  • 04 Oct, 2022
  • 1 location
AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer

cancer subtype, i.e. choice of chemotherapy regimen and hormone receptor (HR) [estrogen receptor and/or progesterone receptor], human epidermal growth factor receptor 2 (HER2) related. Although HR

growth factor
epidermal growth factor
immunohistochemistry
progesterone receptor
docetaxel
  • 0 views
  • 06 May, 2022
  • 1 location
A Phase 2 Study of VLS-101 in Patients With Solid Tumors

This is a study evaluating the efficacy, safety, and pharmacokinetics of zilovertamab vedotin in participants with metastatic solid tumors including previously treated cancers of triple-negative breast cancer (TNBC), non-TNBC HER2-negative breast cancer, non-squamous non-small-cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, and platinum-resistant ovarian cancer. The study will evaluate a …

growth factor
measurable disease
epidermal growth factor
lung carcinoma
progesterone receptor
  • 14 views
  • 28 Oct, 2022
  • 13 locations